PharmAla releases Profitable Q1 Interim Financial Statement and Business Update
31 janv. 2024 10h58 HE
|
PharmAla Biotech
PharmAla releases Profitable Q1 Interim Financial Statement, and will host investor webinar to discuss prominent changes to the business & FDA timelines
PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada
25 janv. 2024 12h09 HE
|
PharmAla Biotech
PharmAla granted a Health Canada Controlled Drugs and Substances Dealer's License
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
24 janv. 2024 09h35 HE
|
PharmAla Biotech
PharmAla recieved a new OTCQB ticker, MDXXF.
Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence
19 janv. 2024 07h30 HE
|
Optimi Health Corp.
Optimi Health granted amendment to its Health Canada Controlled Drugs and Substances Licence.
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
08 janv. 2024 08h55 HE
|
PharmAla Biotech
PharmAla announces that its novel P1 molecule has been accepted by USPTO to its accelerated "Patent Prosecution Highway"
MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation
05 janv. 2024 08h01 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS shares ownership of Lykos with mission-aligned investors, will continue to advance psychedelic research, change drug policy, and shape culture
Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats
03 janv. 2024 07h30 HE
|
Optimi Health Corp.
Optimi Health Granted Precursor Licence for 3,4-Methylenedioxyphenyl-2-propanone (“MDP2P”), the precursor used in the chemical synthesis of MDMA.
PharmAla Files Audited Financials for Year Ending August 31, 2023
29 déc. 2023 16h00 HE
|
PharmAla Biotech
PharmAla releases audited year-end financials for the period ended August 31st.
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD
13 déc. 2023 18h16 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
The first NDA submission for any psychedelic-assisted therapy has been submitted through a 30-year effort initiated and led by the nonprofit MAPS
Optimi Health and Sunshine Earth Labs Ltd. Forge Strategic Supply Agreement
07 déc. 2023 07h30 HE
|
Optimi Health Corp.
Optimi Health and Sunshine Earth Labs Ltd. Forge Strategic Supply Agreement